📊 BDPT Key Takeaways
Investment Thesis
BioAdaptives is a pre-revenue pharmaceutical company in severe financial distress with collapsing revenue (-55.6% YoY), massive operating losses, and negative stockholders' equity of -$1.5M indicating technical insolvency. The company faces immediate existential risk with critically low liquidity (0.07x current ratio), negative free cash flow of -$378.2K, and insufficient cash reserves to sustain operations beyond the near term.
BDPT Strengths
- Positive gross margin of 62.6% on limited revenue indicates potential product economics
- Minimal capital expenditure of $18.0K suggests lean operational structure
- Recent insider trading activity (3 Form 4 filings) shows some stakeholder engagement
BDPT Risks
- Negative stockholders' equity of -$1.5M represents technical insolvency and balance sheet bankruptcy
- Critical liquidity crisis with current ratio of 0.07x and only $59.3K cash against $1.6M liabilities
- Severe revenue decline of 55.6% YoY with operating losses of -$794.1K indicating inability to commercialize or sustain operations
- Negative free cash flow of -$378.2K with no clear path to profitability or cash generation
- Long-term debt of $75.7K against minimal equity and shrinking cash reserves
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue stabilization or achievement of material revenue growth
- Balance sheet restructuring or capital infusion to restore positive equity
- Operating expense reduction or achievement of operating profitability
BDPT Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BDPT Profitability Ratios
BDPT vs Healthcare Sector
How BIOADAPTIVES, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BDPT Balance Sheet & Liquidity
BDPT 5-Year Financial Trend
5-Year Trend Summary: BIOADAPTIVES, INC.'s revenue has grown significantly by 75% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.12 indicates the company is currently unprofitable.
BDPT Growth Metrics (YoY)
BDPT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$37.6K | $0.00 |
| Q2 2025 | $675 | -$157.9K | $0.02 |
| Q1 2025 | N/A | -$197.1K | $-0.02 |
| Q3 2024 | N/A | -$13.1K | N/A |
| Q2 2024 | $675 | -$143.9K | N/A |
| Q1 2024 | $3.4K | -$287.2K | N/A |
| Q3 2023 | $3.3K | -$13.1K | N/A |
| Q2 2023 | $2.3K | -$143.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BDPT Capital Allocation
BDPT SEC Filings
Access official SEC EDGAR filings for BIOADAPTIVES, INC. (CIK: 0001575142)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDPT
What is the AI rating for BDPT?
BIOADAPTIVES, INC. (BDPT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDPT's key strengths?
Positive gross margin of 62.6% on limited revenue indicates potential product economics. Minimal capital expenditure of $18.0K suggests lean operational structure.
What are the risks of investing in BDPT?
Negative stockholders' equity of -$1.5M represents technical insolvency and balance sheet bankruptcy. Critical liquidity crisis with current ratio of 0.07x and only $59.3K cash against $1.6M liabilities.
What is BDPT's revenue and growth?
BIOADAPTIVES, INC. reported revenue of $7.9K.
Does BDPT pay dividends?
BIOADAPTIVES, INC. does not currently pay dividends.
Where can I find BDPT SEC filings?
Official SEC filings for BIOADAPTIVES, INC. (CIK: 0001575142) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDPT's EPS?
BIOADAPTIVES, INC. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.